In the countries of Eastern Europe and Central Asia, 89% of
national government funding for HIV prevention goes on programmes for the
general population, although most countries’ epidemics are dominated by
injecting drug use, Shona Schonning of the Eurasian Harm Reduction Network told the Eighteenth International AIDS
Conference in Vienna
last week.
She was one of a number of speakers who called on the Global
Fund to Fight AIDS, Tuberculosis and Malaria to change its eligibility criteria
so that prevention programmes in Russia and other countries in the
region can continue to receive Global Fund support.
They believe that the Russian government is unwilling or
incapable of responding to the country’s HIV epidemic. Without international
support, the prevention needs of vulnerable groups will be ignored and antiretroviral
treatment stock-outs will become more frequent.
Speakers and activists frequently said that Eastern Europe
and Central Asia now has the fastest growing
HIV epidemic in the world. The number of people living with HIV increased from
900,000 in 2001 to 1,500,000 in 2008, the biggest jump of any world region. (The
region is primarily made up of the countries of the former Soviet Union, and
excludes countries such as Hungary
and Poland.)
“While HIV epidemics in Western Europe are, with some
exceptions, generally stabilising, in many countries in Eastern
Europe, they rage out of control,” Andrew Ball of the World Health
Organization said.
The epidemics in Russia
and Ukraine
are especially severe and rapidly growing. These two countries account for more than 90% of the
region’s total infections. HIV prevalence is above 1% in the general population
of both countries. But it is exceptionally high in injecting drug users: an
estimated 37% in Russia, and
between 38 and 50% in Ukraine.
Other vulnerable populations in the region include sex
workers and prisoners (partly due to drug use in these groups, but also because of sexual
transmission). Prevalence surveys with men who have sex with men suggest that
rates of HIV infection are significantly higher than in the general population.
Senior Russian health officials have said that they oppose
harm-reduction policies (such as supporting needle and syringe exchange), but
instead support ‘supply reduction’. The provision of opioid substitution
treatment (methadone, buprenorphine) is illegal in Russia although these are
classified as essential medicines by the World Health Organization.
Moreover, only 23% of people who need antiretroviral therapy
receive it. Access is therefore poorer than in sub-Saharan Africa (44%) and any
other world region except North Africa & the Middle
East (14%).
Shona Schonning showed differences in the way in which national
governments and international donors spend their money on HIV in the region.
Whereas approximately half of government spending goes on treatment and care,
only around 20% is spent on prevention activities.
The situation is reversed for international donors
– 20%
goes to treatment and care and 50% to prevention.
Moreover, when government spending on prevention is analysed,
only 8% goes to work with injecting drug users, 2% to work with sex workers and
their clients, and 1% to programmes with men who have sex with men. The vast
majority (89%) goes to general population prevention programmes.
She also noted that countries in the region were paying high
prices to pharmaceutical companies and so not making best use of available
resources.
The principal international funding mechanism for countries
in the region has been the Global Fund.
In Russia, both prevention
and treatment programmes in Russia
were supported between 2004 and 2009.
Prevention programmes were delivered by civil society and
non-government organisations, and concentrated on injecting drug users (outreach
services, needle exchange, condoms, and voluntary counselling and testing were
provided), as well as men who have sex with men, street children, sex workers, migrants
and prisoners.
However, under its current eligibility criteria, programmes there
are no longer eligible for Global Fund support. Russia is now an upper
middle-income country, and as such is considered capable of responding to its
own HIV epidemic.
Shona Schonning (and several people who spoke from the floor
at this session) called on the Global Fund to revise its eligibility criteria.
They say that a country’s income level does not by itself determine a country’s
ability to respond effectively to its epidemic. For example, the Russian
government’s approach has been driven by an ideological belief in
abstinence-based approaches rather than scientific evidence. The government has
persistently neglected the needs of its most vulnerable populations.
Global Fund financing for prevention programmes has in fact been
extended for two years “in recognition of the emergency situation that would
have arisen if funding had been discontinued”. Nonetheless, unless either the
criteria of the Global Fund or the health policies of the Russian government
change dramatically, the future of prevention work in Russia in 2012
and beyond looks bleak.
The treatment component of the Global Fund grant has been
taken over by the Russian government. Since then, activists have reported
shortages of drug supply in many regions and forced treatment interruptions in
five regions. Moreover, it is generally difficult for migrants and for
prisoners to gain access to treatment.